JP2017526714A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526714A5 JP2017526714A5 JP2017513648A JP2017513648A JP2017526714A5 JP 2017526714 A5 JP2017526714 A5 JP 2017526714A5 JP 2017513648 A JP2017513648 A JP 2017513648A JP 2017513648 A JP2017513648 A JP 2017513648A JP 2017526714 A5 JP2017526714 A5 JP 2017526714A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- paag
- composition according
- administered
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000019693 Lung disease Diseases 0.000 claims description 9
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 7
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 201000009267 bronchiectasis Diseases 0.000 claims description 2
- 230000001886 ciliary effect Effects 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 72
- 239000004599 antimicrobial Substances 0.000 claims 9
- 239000004475 Arginine Substances 0.000 claims 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 3
- 230000000845 anti-microbial effect Effects 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 208000004852 Lung Injury Diseases 0.000 claims 2
- 206010069363 Traumatic lung injury Diseases 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 231100000515 lung injury Toxicity 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 239000004821 Contact adhesive Substances 0.000 claims 1
- 241000186359 Mycobacterium Species 0.000 claims 1
- 241001502334 Mycobacterium avium complex bacterium Species 0.000 claims 1
- 229960004821 amikacin Drugs 0.000 claims 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 1
- 229960004099 azithromycin Drugs 0.000 claims 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims 1
- 229960003644 aztreonam Drugs 0.000 claims 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960000285 ethambutol Drugs 0.000 claims 1
- 229960002442 glucosamine Drugs 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 1
- 229960001225 rifampicin Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 210000004072 lung Anatomy 0.000 description 7
- 201000009805 cryptogenic organizing pneumonia Diseases 0.000 description 4
- 206010067472 Organising pneumonia Diseases 0.000 description 3
- 206010006448 Bronchiolitis Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000033116 Asbestos intoxication Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 241000342334 Human metapneumovirus Species 0.000 description 1
- 206010025219 Lymphangioma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 208000011191 Pulmonary vascular disease Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 208000010123 anthracosis Diseases 0.000 description 1
- 206010003441 asbestosis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462049082P | 2014-09-11 | 2014-09-11 | |
| US62/049,082 | 2014-09-11 | ||
| PCT/US2015/049835 WO2016040899A1 (en) | 2014-09-11 | 2015-09-11 | Compositions and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017526714A JP2017526714A (ja) | 2017-09-14 |
| JP2017526714A5 true JP2017526714A5 (cg-RX-API-DMAC7.html) | 2020-02-13 |
Family
ID=55459642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513648A Pending JP2017526714A (ja) | 2014-09-11 | 2015-09-11 | 組成物およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20170304355A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4420518A3 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017526714A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20170094121A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2015314775A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2960998A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016040899A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2806559C (en) | 2009-09-02 | 2018-06-26 | Synedgen Inc. | Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds |
| CA2795520C (en) | 2010-04-06 | 2018-03-06 | Synedgen Inc. | Methods and compositions for treating wounds utilizing chitosan compounds |
| WO2014047506A1 (en) | 2012-09-20 | 2014-03-27 | Synedgen, Inc. | Methods for treatment or prevention of damage resulting from radiation, trauma or shock |
| JP2017526714A (ja) | 2014-09-11 | 2017-09-14 | シネジェン， インコーポレイテッド | 組成物およびその使用方法 |
| EP3429602B1 (en) * | 2016-03-16 | 2025-05-07 | Synedgen, Inc. | Compositions comprising a polyglucosamine-arginine and their use to treat dysbiosis |
| WO2018217764A1 (en) * | 2017-05-22 | 2018-11-29 | Kansas State University Research Foundation | Microbiome transplantation |
| US12478661B2 (en) | 2017-10-03 | 2025-11-25 | The Johns Hopkins University | Lung cell treatments to prevent or treat disease |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| AU2020444897A1 (en) * | 2020-04-30 | 2022-12-08 | Synedgen, Inc. | Compositions and methods of use thereof |
| WO2025189143A1 (en) * | 2024-03-08 | 2025-09-12 | Synedgen, Inc. | Compositions and methods of their use |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6436950B1 (en) | 1998-08-14 | 2002-08-20 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of apomorphine |
| EP1139746A4 (en) * | 1998-12-22 | 2003-09-17 | Univ North Carolina | CONNECTIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISEASES AND THE ADMINISTRATION OF MEDICINAL SUBSTANCES |
| US20030087414A1 (en) * | 2001-11-02 | 2003-05-08 | Aerts Johannes Maria Franciscus Gerardus | Mammalian mucinase, its recombinant production, and its use in therapy or prophylaxis against diseases in which mucus is involved or infectious diseases |
| US20030181416A1 (en) | 2002-01-10 | 2003-09-25 | Comper Wayne D. | Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof |
| GB0300597D0 (en) | 2003-01-10 | 2003-02-12 | Microbiological Res Authority | Phage biofilms |
| US7850970B2 (en) | 2003-08-26 | 2010-12-14 | The Regents Of The University Of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
| PE20050941A1 (es) * | 2003-12-16 | 2005-11-08 | Nycomed Gmbh | Suspensiones acuosas de ciclesonida para nebulizacion |
| WO2006124892A2 (en) * | 2005-05-13 | 2006-11-23 | Whitehead Institute For Biomedical Research | Modulators of alpha-synuclein toxicity |
| JP2009522328A (ja) * | 2006-01-06 | 2009-06-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗コリン作用薬及びアンドラストを基にした新規な医薬組成物 |
| EP3144324A1 (en) | 2006-06-02 | 2017-03-22 | Synedgen, Inc. | Chitosan-derivative compounds and methods of controlling microbial populations |
| JP2010507617A (ja) * | 2006-10-26 | 2010-03-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器系及び消化器系障害の治療用の新規な医薬組成物 |
| EP2121026B1 (en) | 2006-12-11 | 2017-06-28 | CHIT2GEL Ltd. | Novel injectable chitosan mixtures forming hydrogels |
| US9012429B2 (en) | 2008-08-16 | 2015-04-21 | Synedgen, Inc. | Methods and compositions for the prevention of and treatment of infections utilizing chitosan-derivative compounds |
| EP2364153B1 (en) | 2008-11-12 | 2015-05-06 | Synedgen, Inc. | Chitosan derivatives to optimize animal weight gain |
| AU2009313937B2 (en) * | 2008-11-12 | 2014-11-13 | Synedgen, Inc. | Chitosan derivatives alone or in combination for the treatment of MDR microbial infections |
| WO2010088565A1 (en) | 2009-01-29 | 2010-08-05 | Synedgen, Inc. | Nucleic acid delivery using modified chitosans |
| JP2013503897A (ja) | 2009-09-02 | 2013-02-04 | シネジェン， インコーポレイテッド | キトサン誘導体化合物を用いる口腔ケア方法および組成物 |
| CA2806559C (en) * | 2009-09-02 | 2018-06-26 | Synedgen Inc. | Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds |
| EP2533761B1 (en) * | 2010-02-11 | 2019-03-27 | Ablynx N.V. | Methods and compositions for the preparation of aerosols |
| CA2795520C (en) * | 2010-04-06 | 2018-03-06 | Synedgen Inc. | Methods and compositions for treating wounds utilizing chitosan compounds |
| US20140221308A1 (en) | 2011-07-01 | 2014-08-07 | Synedgen, Inc. | Methods and compositions of reducing and preventing bacterial growth and the formation of biofilm on a surface utilizing chitosan-derivative compounds |
| US20150031610A1 (en) | 2012-03-05 | 2015-01-29 | Synedgen, Inc. | Derivatized polyglucosamines for delivery of small molecules, peptides, and proteins |
| WO2014047506A1 (en) | 2012-09-20 | 2014-03-27 | Synedgen, Inc. | Methods for treatment or prevention of damage resulting from radiation, trauma or shock |
| CA2905404C (en) | 2013-03-12 | 2021-07-20 | Synedgen, Inc. | Oral formulations of polyglucosamine derivatives in combination with a non-fermentable sugar |
| JP2016519667A (ja) | 2013-03-15 | 2016-07-07 | シネジェン， インコーポレイテッド | 創傷治癒のための組成物および使用方法 |
| JP6300360B2 (ja) | 2013-05-27 | 2018-03-28 | 大阪エヌ・イー・ディー・マシナリー株式会社 | 球体回転機構及び球体表面検査装置 |
| JP2017526714A (ja) | 2014-09-11 | 2017-09-14 | シネジェン， インコーポレイテッド | 組成物およびその使用方法 |
| US20180153807A1 (en) | 2015-04-22 | 2018-06-07 | Matinas Biopharma Nanotechnologies, Inc. | Compositions and methods for treating mycobacteria infections and lung disease |
| AU2020444897A1 (en) | 2020-04-30 | 2022-12-08 | Synedgen, Inc. | Compositions and methods of use thereof |
-
2015
- 2015-09-11 JP JP2017513648A patent/JP2017526714A/ja active Pending
- 2015-09-11 EP EP24169131.0A patent/EP4420518A3/en active Pending
- 2015-09-11 WO PCT/US2015/049835 patent/WO2016040899A1/en not_active Ceased
- 2015-09-11 CA CA2960998A patent/CA2960998A1/en not_active Abandoned
- 2015-09-11 KR KR1020177009338A patent/KR20170094121A/ko not_active Withdrawn
- 2015-09-11 EP EP15840207.3A patent/EP3190886B1/en active Active
- 2015-09-11 AU AU2015314775A patent/AU2015314775A1/en not_active Abandoned
- 2015-09-11 US US15/510,478 patent/US20170304355A1/en not_active Abandoned
-
2019
- 2019-09-17 US US16/573,559 patent/US11957707B2/en active Active
-
2020
- 2020-01-29 AU AU2020200603A patent/AU2020200603B2/en active Active
-
2024
- 2024-02-27 US US18/588,605 patent/US20240350529A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526714A5 (cg-RX-API-DMAC7.html) | ||
| JP2011520911A5 (cg-RX-API-DMAC7.html) | ||
| JP2016513688A5 (cg-RX-API-DMAC7.html) | ||
| AU2008310734B2 (en) | Delivering osmolytes by nasal cannula | |
| CA2773033C (en) | Use of aerosolized levofloxacin for treating cystic fibrosis | |
| US20120070417A1 (en) | Anti-influenza formulations and methods | |
| RS52239B (sr) | Farmaceutske formulacije i metode za tretman infekcija respiratornog trakta | |
| EP2410985A2 (en) | Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis | |
| JP2013503907A5 (cg-RX-API-DMAC7.html) | ||
| MD4369B1 (ro) | Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei | |
| US10471083B2 (en) | Formulations of aminoglycoside and fosfomycin in combination for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis | |
| JP2022554352A (ja) | クロファジミンの組成物、それを含む組合せ、その調製プロセス、それを含む使用及び処置方法 | |
| JP5501451B2 (ja) | 咳の治療のためのテオブロミン | |
| WO2012142367A2 (en) | Compositions and methods for treatment of pulmonary diseases and conditions | |
| US8826904B2 (en) | Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis | |
| JP2016535774A (ja) | 多剤耐性結核治療のための噴霧吸入による免疫化学療法 | |
| JP2016502992A5 (cg-RX-API-DMAC7.html) | ||
| JP2017513866A5 (cg-RX-API-DMAC7.html) | ||
| JP2013522295A5 (cg-RX-API-DMAC7.html) | ||
| Kuzovlev et al. | Inhaled antibiotics in treatment of nosocomial pneumonia | |
| US20240299379A1 (en) | Compositions of clofazimine and amikacin for pulmonary administration in the treatment of respiratory diseases | |
| US9526697B2 (en) | Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis | |
| AU2017225010A1 (en) | Delivering osmolytes by nasal cannula | |
| Savoschin | Administrarea prin nebulizare a soluţiei saline hipertonice 3% la copiii cu sindrom obstructiv bronşic: studiu clinic randomizat | |
| WO2021205074A1 (en) | Inhalable formulation |